Detection of MRP functional activity: Calcein AM but not BCECF AM as a multidrug resistance-related protein (MRP1) substrate

被引:57
作者
Olson, DP [1 ]
Taylor, BJ [1 ]
Ivy, SP [1 ]
机构
[1] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Washington, DC 20010 USA
来源
CYTOMETRY | 2001年 / 46卷 / 02期
关键词
pediatric leukemia; chemotherapy resistance; MDR; MRP; flow cytometry;
D O I
10.1002/cyto.1072
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Resistance to anticancer drugs has been attributed to an array of cellular changes. The multidrug resistance-related protein (MRP1) is an efflux pump whose overexpression confers resistance to several classes of drugs, such as the anthracyclines, epipodophyllotoxins, and vinca alkaloids, These drugs are mainstays in cancer therapy. MRP1 overexpression is hypothesized to be a causative agent of clinical treatment failure. Consistently accurate methods for detecting this protein are necessary to further understand its biology and delineate its possible clinical relevance, Flow cytometric analysis of multidrug resistance (MDR) is a valuable method to evaluate both antigen expression and function, Using flow cytometry, we assayed MRP1 functional activity in pediatric leukemic blasts and an array of MDR+ and WT cell lines, We conclude that calcein AM, when used in a retention assay with MRP1-specific modulators, is able to reliably detect MRP functional activity. 2'-7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF AM) transport is not indicative of MRP1 overexpression. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:105 / 113
页数:9
相关论文
共 30 条
[1]   EFFLUX OF BIS-CARBOXYETHYL-CARBOXYFLUORESCEIN (BCECF) BY A NOVEL ATP-DEPENDENT TRANSPORT MECHANISM IN EPITHELIAL-CELLS [J].
ALLEN, CN ;
HARPUR, ES ;
GRAY, TJB ;
SIMMONS, NL ;
HIRST, BH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 172 (01) :262-267
[2]  
ALMQUIST KC, 1995, CANCER RES, V55, P102
[3]  
Arceci R J, 1996, Curr Opin Hematol, V3, P279
[4]   HIGH MDR1- AND MRP-, BUT LOW TOPOISOMERASE-II ALPHA-GENE EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIAS [J].
BECK, J ;
NIETHAMMER, D ;
GEKELER, V .
CANCER LETTERS, 1994, 86 (01) :135-142
[5]  
BECK J, 1995, CANC LETT, V2, P227
[6]   Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins [J].
Belinsky, MG ;
Bain, LJ ;
Balsara, BB ;
Testa, JR ;
Kruh, GD .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (22) :1735-1741
[7]  
Berger W, 1997, INT J CANCER, V71, P108, DOI 10.1002/(SICI)1097-0215(19970328)71:1<108::AID-IJC18>3.0.CO
[8]  
2-E
[9]  
Berger W, 1997, INT J CANCER, V73, P84
[10]  
Broxterman Henk J., 1995, Current Opinion in Oncology, V7, P532, DOI 10.1097/00001622-199511000-00011